- ►annals.org [PDF] CP Gross, GJ McAvay, HM Krumholz, AD Paltiel … - Annals of internal medicine, 2006 - Am Coll Physicians Background: Older adults with shorter life expectancies may re- ceive less
benefit from colorectal cancer screening than younger, healthier patients. ...
Objective: To determine the degree to which life expectancy after diagnosis ... Cited by 45 - Related articles - BL Direct - All 7 versions
CW Ko, A Sonnenberg - Gastroenterology, 2005 - Elsevier Background & Aims: In patients with limited life expectancy, the risks of
colorectal cancer screening may outweigh the benefits. The aim of this study was
to quantify risks and benefits of different screening strategies in elderly ... Cited by 40 - Related articles - All 15 versions
EC Popa, W Luo, H Hochster, B Lyman, M … - Journal of Clinical Oncology, 2005 - Am Soc Clin Oncol Background: UFT, an oral fluoropyrimidine consisting of Tegafur plus uracil (1:4
molar ratio), constitutes a readily absorbed combination agent inhibiting DPD
and is reliably converted to 5FU. LV has been added to each dose in order ... Cited by 9 - Related articles - All 3 versions
OS Lin, RA Kozarek, DB Schembre, K Ayub, … - Jama, 2006 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. Cited by 56 - Related articles - BL Direct - All 5 versions
A Figer, N Perez, E Carola, T Andre, I … - Journal of Clinical Oncology, 2004 - Am Soc Clin Oncol Background: Pts with age over 75 years are usually excluded from randomised
studies. OPTIMOX trial consisted in a phase III study for pts with conventional
inclusion criteria (526 pts), comparing FOLFOX4 to FOLFOX7 x 6 cycles, ... Cited by 14 - Related articles - All 2 versions
DY Oh, YJ Kim, SW Han, IS Choi, JH Kim, DW … - Journal of Clinical Oncology, 2005 - Am Soc Clin Oncol Background: Elderly patients are underrepresented in clinical trials, and are
often denied of palliative chemotherapy due to limited evidence of efficacy and
fear of toxicities. To minimize toxicity and improve compliance of ... Cited by 7 - Related articles - All 2 versions
A Comandone, P Pochettino, P Bergnolo, A … - ASCO Meeting Abstracts, 2005 - meeting.ascopubs.org Background: Oral Capecitabine (CAP) is a highly effective chemotherapy agent for
treatment of advanced colorectal cancer (ACRC), demonstrating superior
antitumour activity and an improved safety profile versus 5-FU/LV. CAP ... Cited by 7 - Related articles - All 4 versions
- ►oxfordjournals.org R Mattioli, C Massacesi, F Recchia, F Marcucci … - Annals of Oncology, 2005 - Eur Soc Med Oncology Patients and methods:: This multicenter phase II study was designed to
investigate feasibility, efficacy, activity of daily living (ADL) and
instrumental activity of daily living (IADL) in elderly patients with ... Cited by 23 - Related articles - All 5 versions
MC Cripps, M Vincent, D Jonker, I Kerr, B … - ASCO Meeting Abstracts, 2005 - meeting.ascopubs.org Background: Combination chemotherapy results in improved outcomes in trials of
selected fit patients with ACRC. For older, less fit, more complicated patients,
combination chemotherapy is associated with greater toxicity and less ... Cited by 10 - Related articles - All 2 versions
J Souglakos, A Pallis, S Kakolyris, D … - Oncology, 2005 - content.karger.com Purpose: To evaluate the efficacy and tolerance of irinotecan (CPT-11) in
combination with bolus and continuous infusion of 5-fluorouracil (5-FU) and
leucovorin (LV) (FOLFIRI regimen) as first-line treatment of elderly ... Cited by 28 - Related articles - BL Direct - All 5 versions
